Indirect effect of protocatechuic acid on gut inflammation by modulating lithocholic acid-mediated TAK1 signaling

Technical Summary: Indirect Effect of Protocatechuic Acid on Gut Inflammation by Modulating Lithocholic Acid-Mediated TAK1 Signaling

Problem Statement
Gut inflammation and subsequent mucosal barrier dysfunction are critical challenges in swine production, particularly during the weaning period. Stress-induced dysfunctions in digestion, absorption, and immune responses often lead to growth inhibition and diarrhea. The underlying mechanisms involve the activation of Transforming Growth Factor Beta-Activated Kinase 1 (TAK1), a pivotal serine/threonine kinase in innate immune signaling. Upon activation by bacterial lipopolysaccharides (LPS) and inflammatory cytokines, TAK1 triggers the NF-κB and MAPK pathways, leading to the production of pro-inflammatory cytokines (e.g., IL-6, TNF-α) and the downregulation of tight junction proteins (e.g., Occludin, ZO-1), thereby compromising intestinal integrity. While plant-derived phenolic compounds like protocatechuic acid (PCA) have shown anti-inflammatory potential, the specific molecular mechanism by which PCA alleviates gut inflammation, particularly regarding its interaction with TAK1, remained unclear.

Methodology
The study employed a multi-tiered approach involving in vivo animal models, in vitro cell cultures, and advanced biochemical analyses:

1. Piglet Model: 108 weaned piglets were divided into control (CTL), LPS-induced inflammation (LPS), and PCA-supplemented LPS (PCA+LPS) groups. Piglets received 400 mg/kg PCA for 28 days, with LPS challenges on days 21 and 28. Parameters included growth performance, diarrhea rates, serum biochemistry, and ileal tissue histology.
2. Fecal Microbiota Transplantation (FMT): To isolate the role of the microbiome, fecal suspensions from the piglet groups were transplanted into antibiotic-treated mice (CTL_F, LPS_F, PCA_F) to observe the transfer of inflammatory phenotypes and barrier function.
3. Bile Acid Gavage: A separate mouse model was used to administer Lithocholic Acid (LCA) directly to verify its specific anti-inflammatory effects and mechanism.
4. Cellular Models: RAW 264.7 macrophages were used to assess cell viability, inflammatory cytokine expression, and TAK1 phosphorylation kinetics under LPS and LCA treatments.
5. Molecular and Biochemical Assays:
   • Omics: 16S rDNA sequencing for gut microbiota characterization and targeted metabolomics for bile acid profiling.
   • Protein Analysis: Western blotting and immunofluorescence for TAK1, NF-κB, MAPK, and tight junction protein expression.
   • Binding Studies: In vitro pull-down assays to test PCA-TAK1 binding; Isothermal Titration Calorimetry (ITC) and Molecular Modeling (MOE software) to characterize the LCA-TAK1 interaction, specifically focusing on binding affinity and catalytic site occupancy.

Key Results

• PCA Alleviates Inflammation Indirectly: PCA supplementation significantly reduced diarrhea rates, lowered serum inflammatory cytokines (IL-1β, IL-6, TNF-α), and restored intestinal barrier integrity (increased ZO-1 and Occludin) in LPS-challenged piglets. Crucially, while PCA inhibited TAK1 phosphorylation in vivo, in vitro pull-down assays confirmed that PCA does not directly bind to TAK1.
• Microbiota Remodeling: PCA supplementation altered the gut microbiota composition, specifically increasing the relative abundance of Rikenellaceae and Catenisphaera. This remodeling correlated with an enrichment of the secondary bile acid biosynthesis pathway.
• LCA as the Mediator: Metabolomic analysis revealed that PCA treatment significantly increased fecal levels of secondary bile acids, particularly Lithocholic Acid (LCA). FMT experiments demonstrated that mice receiving PCA-remodeled microbiota exhibited reduced inflammation and improved barrier function, mirroring the PCA+LPS piglet group.
• LCA Directly Targets TAK1: Direct administration of LCA in mice and cells suppressed LPS-induced inflammation and TAK1 phosphorylation.
  • Binding Mechanism: ITC and molecular docking confirmed that LCA binds directly to the catalytic site of TAK1.
  • Specific Residues: LCA occupies the catalytic pocket, interacting with key residues Met104 and Lys63. This binding disrupts the critical ion pair between Lys63 and Asp175, obstructs ATP binding, and inhibits the kinase activity of TAK1.
• Downstream Effects: The inhibition of TAK1 phosphorylation by LCA led to the suppression of downstream NF-κB and MAPK pathways, reducing pro-inflammatory cytokine production and upregulating tight junction proteins.

Key Contributions

1. Mechanistic Clarification: The study delineates a "gut microbiota–metabolite–host" axis, demonstrating that PCA exerts its anti-inflammatory effects not through direct kinase inhibition, but by enriching gut microbiota to produce LCA.
2. Discovery of a Natural TAK1 Inhibitor: This work identifies LCA as a natural, direct inhibitor of TAK1. It is the first report characterizing LCA's ability to bind specifically to the TAK1 catalytic site (Met104 and Lys63) to inhibit phosphorylation.
3. Therapeutic Insight: The research provides a molecular basis for using PCA as a feed additive to improve gut health in weaned piglets by leveraging the host-microbiome interaction to modulate inflammatory signaling.

Significance and Claims
The authors claim this study offers a novel perspective on how bioactive compounds mitigate inflammation. Rather than acting as direct kinase inhibitors, compounds like PCA can function as "microbiome sculptors," modulating the host's metabolic environment to generate bioactive metabolites (like LCA) that directly target inflammatory hubs.

The paper concludes that the PCA-LCA-TAK1 axis represents a viable therapeutic strategy for gut inflammation. By competitively inhibiting TAK1 phosphorylation, LCA reduces the "attack" (inflammatory cytokine production) and strengthens the "defense" (tight junction integrity). The authors note that while the findings are robust in piglet and murine models, the specific structural biology of the LCA-TAK1 interaction requires further validation, and the applicability to other species warrants future investigation. Nevertheless, the discovery of LCA as a natural TAK1 inhibitor offers new lead compounds for the development of anti-inflammatory therapeutics.